GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vilacto Bio Inc (GREY:VIBI) » Definitions » Debt-to-EBITDA

Vilacto Bio (Vilacto Bio) Debt-to-EBITDA : -1.72 (As of Jun. 2019)


View and export this data going back to 2013. Start your Free Trial

What is Vilacto Bio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vilacto Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2019 was $2.28 Mil. Vilacto Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2019 was $0.00 Mil. Vilacto Bio's annualized EBITDA for the quarter that ended in Jun. 2019 was $-1.33 Mil. Vilacto Bio's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2019 was -1.72.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vilacto Bio's Debt-to-EBITDA or its related term are showing as below:

VIBI's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Debt-to-EBITDA only.

Vilacto Bio Debt-to-EBITDA Historical Data

The historical data trend for Vilacto Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vilacto Bio Debt-to-EBITDA Chart

Vilacto Bio Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19
Debt-to-EBITDA
Get a 7-Day Free Trial - - -2.62 -0.28 -0.43

Vilacto Bio Quarterly Data
Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 -0.06 -0.25 -0.56 -1.72

Competitive Comparison of Vilacto Bio's Debt-to-EBITDA

For the Biotechnology subindustry, Vilacto Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vilacto Bio's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vilacto Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vilacto Bio's Debt-to-EBITDA falls into.



Vilacto Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vilacto Bio's Debt-to-EBITDA for the fiscal year that ended in Mar. 2019 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.481 + 0) / -5.712
=-0.43

Vilacto Bio's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2019 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.283 + 0) / -1.328
=-1.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2019) EBITDA data.


Vilacto Bio  (GREY:VIBI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Vilacto Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vilacto Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vilacto Bio (Vilacto Bio) Business Description

Traded in Other Exchanges
N/A
Address
Fabriksvej 48, Suite 2607, The Seagram Building, Naestved, DNK, 4700
Vilacto Bio Inc is a biotech company. It operates a fully patented Lactoactive molecule for treating conditions such as inflammatory diseases, diabetics, psoriasis, and skin issues in different levels. The company is also intended to develop Lactoactive molecule for increasing the quality of its retail and medical skin cream product as well as developing products for medical applications. Its product portfolio includes lotions, skin care creams and gels, lip balms, foot creams and oils, and others.